Estrogen use has been associated with an increased risk for breast cancer and endometrial cancers in women (1-4). Various natural and synthetic estrogens also induce mammary, pituitary, cervical, uterine, and renal tumors in rodents (4-5). Diethylstilbestrol (DES), a synthetic estrogen, is well known to be carcinogenic to humans (6). The cellular and molecular mechanism(s) whereby estrogen-induced neoplastic events occur have not been fully elucidated, but there is strong evidence that estrogens are epigenetic carcinogens, acting via a promoting effect related to cellular proliferation, mediated through the estrogen receptor (7-15). However, it has been shown that estrogenic activity is not sufficient to explain the carcinogenic activity in vivo and in vitro under certain experimental conditions. Another mechanism, related to mutagenic changes, has been suggested in studies of estrogen-induced carcinogenesis (16)(17)(18)(19)(20)(21)(22)(23)(24) into the cellular and molecular mechanisms of carcinogenesis, which is difficult in whole-animal or human systems. We have used Syrian hamster embryo (SHE) fibroblast cell cultures as a model system to study the ability of estrogens to directly transform cells.
Morphological and Neoplastic Transformation in Vitro by Estrogens and Estrogenlike ChemicalsMorphological and neoplastic transformation of SHE cells is induced by DES, 17,-estradiol (E2) and other estrogens. We observed that DES and E2 induce transformation of hamster cells that is indistinguishable from that induced by other chemical carcinogens such as benzo [a]pyrene (19,25). Sarcomas are also induced in Syrian hamsters in vivo following subcutaneous injection of DES (26). SHE cells do not express measurable levels of estrogen receptor and estrogen treatment is not mitogenic to the cells (27). Thus, estrogenic activity of the compounds can be excluded in this in vitro assay. The cells do, however, have the ability to metabolize estrogens (28,29), and the role of metabolic activation in the carcinogenesis activity of estrogens in this model is under investigation as discussed later.The role of mutagenesis in the neoplastic transformation of SHE cells by estrogens has been studied extensively. We have demonstrated that treatment of SHE cells with DES or E2 induces cell transformation without measurable gene mutations, unscheduled DNA synthesis (UDS) or structural chromosome aberrations (19,20,23